Skip to main content

Table 1 CD20-CD3 bispecific T cell engager for relapsed or refractory diffuse large B cell lymphoma

From: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Agent Odronextamab Mosunetuzumab Epcoritamab Glofitamab
Targets CD20, CD3 CD20, CD3 CD20, CD3 CD20, CD3
IG Human IgG4 Human IgG1 Human IgG1 Human IgG
Administration i.v s.c i.v i.v
Patients (n) 35 22 18 28
Median prior therapy 3 (1–11) 4 (1–8) NA 3 (1–12)
Prior CAR T 69% 22% NA NA
ORR 44% 60% 67% 50%
CR 38% 20% 33% 29%
PFS NR NR NR NR
OS NR NR NR NR
CRS, any grade 63% 21% 58% 57.9%
  ≥ 3 5% 0 0 3.8%
NT, any grade 0 22% 9% 0
  ≥ 3 0 0 3% 0
Reference [24] [25] [26] [27]
  ASH,2020, #400 ASH,2020, #401 ASH,2020, #403 ASH,2020, #404